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INTRODUCTION
Infectious disease epidemics pose a threat 
to reproductive, maternal, newborn and 
child health (RMNCH) both directly—by 
worsening women’s and children’s health 
outcomes—and indirectly—by reducing their 
access to services.1–4 Greater investment is 
therefore needed to mitigate the negative 
effects of COVID-19 and avoid a reversal 
of recent gains in RMNCH coverage and 
outcomes.1 However, COVID-19 has reduced 
household and government budgets,5 and 
there are concerns about the extent to which 
resources have been diverted away from 
RMNCH.1
Alongside domestic government financing 
and household out- of- pocket expenditure, 
aid plays a substantial role in funding RMNCH 
services in many countries. In 2018, for 
example, aid accounted for 25% of current 
health expenditure in the 45 least devel-
oped countries.6 Across the 23 countries with 
RMNCH expenditure estimates for 2018, aid 
accounted for a median of 22% of RMNCH 
expenditure, ranging from <1% in Namibia 
and the Seychelles up to 64% of child health 
and 84% of reproductive and maternal health 
expenditure in South Sudan.6 Yet, aid is vola-
tile,7 subject to changing political priorities 
and not always responsive to needs.6 Global 
economic crises can lead to reduced aid 
levels and change the nature and sources of 
funding.8 Tracking disbursements of aid for 
RMNCH is therefore important for holding 
donors accountable for their commitments, 
including before, during and after crises.
THE MUSKOKA2 METHOD FOR TRACKING AID FOR 
RMNCH
The Muskoka2 method was previously devel-
oped to track aid for RMNCH as part of a 
collaboration between academics, donors and 
other stakeholders, including the Countdown 
to 2030 and the Partnership for Maternal 
Newborn & Child Health.9 The Muskoka2 
method was designed to enable the analysis 
of both donors’ fulfilment of their commit-
ments and the patterns of distribution of aid 
for RMNCH across recipients in a way that 
was efficient, timely, accurate, predictable 
and transparent. Muskoka2 sought to retain 
the simplicity and transparency of the orig-
inal Muskoka approach, which was developed 
by G8 donors, while incorporating eight inno-
vations to improve accuracy and enable more 
granular, recipient- level analyses by drawing 
on the strengths of the earlier Countdown to 
2015 approach.
Muskoka2 is an algorithm applied to aid 
datasets maintained by the Organisation 
for Economic Cooperation and Develop-
ment (OECD). The OECD datasets reflect 
aid reported by donors themselves in a 
comparable format, covering all develop-
ment sectors. While the donors classify their 
Summary box
 ► Greater investment in reproductive, maternal, new-
born and child health (RMNCH) is needed to miti-
gate the negative effects of COVID-19 and avoid a 
reversal of recent gains in RMNCH coverage and 
outcomes.
 ► Aid for RMNCH as a whole fell by 6% between 2017 
and 2018 and only increased by 2% in 2019; over 
the same 2- year period, aid for the reproductive 
health of non- pregnant women fell by 25%.
 ► Volatile and falling aid for RMNCH may have ren-
dered RMNCH systems more fragile in the 2 years 
preceding the COVID-19 pandemic.
 ► We encourage everyone—academics, advocates 
and policy makers—to explore and exploit the 
Muskoka2 aid for RMNCH dataset and other aid 
datasets, as part of efforts to improve RMNCH 
outcomes.
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reported aid by sector and subsectoral purpose, the cate-
gories do not permit straightforward estimates of aid for 
RMNCH. Conceptual and technical choices are therefore 
necessary to identify the share of total aid (to all sectors) 
to count within estimates of aid for RMNCH.
Consistent with the conceptualisation of RMNCH 
within the Every Woman Every Child Global Strategy,10 
the Muskoka2 method seeks to estimate the monetary 
value of aid directly contributing to improvements in 
RMNCH outcomes. It therefore includes the full mone-
tary value of aid categorised by donors as being directed 
towards reproductive health and family planning and 
includes relevant shares of aid directed towards HIV, 
malaria and other infectious diseases; health systems and 
basic healthcare; the humanitarian and water and sani-
tation sectors; and general budget support. The shares 
of aid for HIV, malaria, tuberculosis and general budget 
support counted towards RMNCH vary between recip-
ient countries and over time to account for differences 
in demography, epidemiology and health spending. 
Muskoka2 is therefore suitable for use in analyses of the 
distribution of aid across recipient countries. Muskoka2 
produces separate estimates of aid for maternal and 
newborn health, aid for the health of children aged 
1–59 months and aid for the reproductive health of non- 
pregnant women.
We applied the Muskoka2 method to the most recent 
OECD datasets (January 2021 release).11 We included 
all disbursement data on official development assis-
tance loans and grants and private development finance. 
To provide a picture of the aid landscape just before 
COVID-19 emerged, we present disbursements from 
the 48 donor countries, 35 multilateral institutions and 
10 private donors reporting for both 2015 and 2019—
that is, across the 5 years leading up to the pandemic 
(figure 1)—and focus on changes since 2017, the year for 
which estimates of RMNCH aid were last published.9 12
FALLING AID FOR RMNCH
Aid for RMNCH fell by 6% from $16.7 billion (constant 
2018 US dollars) in 2017 to $15.6 billion in 2018, and 
only increased by 2% in 2019, to $15.9 billion. In the 
same period, total aid for all sectors increased from $262 
billion in 2017 to $267 billion in 2018 (2%) and again 
by 2% in 2019, reaching $273 billion, indicating falling 
prioritisation of RMNCH.
The reduction in aid for RMNCH from 2017 to 2018 
was largely driven by a collective decrease (−18%, 
−$643 million) in disbursements from smaller donors 
(outside the top 10, see figure 1) and decreases by 
the USA (−$287 million, −5%), European Union 
(−$198 million, −29%) and Japan (−$58 million, −11%). 
From 2018 to 2019, the USA further decreased its aid 
for RMNCH (−$1163 million, −20%)—mostly through 
reductions in support for HIV/AIDS—as did the Neth-
erlands (−$77 million, −15%) and Canada (−$46 million, 
−8%). These 2018–2019 reductions were, however, offset 
by a 30% ($1459 million) increase in aid for RMNCH 
from multilateral institutions, notably UNICEF, GAVI, 
the Global Fund and United Nations Population Fund 
(UNFPA).
From 2017 to 2018, aid for child health, maternal and 
newborn health, and the reproductive health of non- 
pregnant women fell by 7%, 5% and 6%, respectively. 
Over the 2- year period from 2017 to 2019, however, aid 
for child health increased overall by 9% to $8.2 billion 
and aid for maternal and newborn health increased 
by 2% to $3.2 billion, whereas aid for the reproductive 
health of non- pregnant women fell by 25% to $4.2 billion. 
Low- income countries collectively received an increasing 
share of aid for RMNCH (34% in 2019), but the value of 
this aid fell from $5063 million in 2017 to $4965 million 
in 2018 (−2%), before rising by 8% to $5363 million in 
2019.
CHALLENGES IN TRACKING RESOURCE FLOWS FOR RMNCH
These estimates are, of course, imperfect. Some donors, 
including China, do not report their aid to the OECD, 
so we may underestimate aid to some degree.13 Donors 
do not all report their aid entirely accurately, and there 
are substantial reporting delays; we will have to wait until 
early 2022 for the OECD to release sufficiently detailed 
disbursement data to estimate aid for RMNCH in 2020.
While the Muskoka2 method offers many advantages, it 
cannot estimate the contribution to RMNCH of individual 
projects and, as an algorithm, it inevitably involves simpli-
fications and assumptions, which have been discussed in 
detail elsewhere.9 Muskoka2 does not produce disaggre-
gated estimates of aid to family planning or newborn or 
adolescent health; key term searches and manual coding 
may be used to explore these and other areas within the 
data.
Two other approaches are used to track aid for 
RMNCH in quite different ways.14 One approach, the 
RMNCH policy marker, is implemented by donors 
themselves within the OECD’s aid activities database. 
Donors are asked to code each aid activity they report 
according to whether it fully, partially or does not 
support RMNCH. The approach is thus not designed 
to produce estimates of aid for RMNCH and donors 
report inconsistently, limiting its usefulness for aid 
tracking, despite the apparent advantages of individ-
ually categorising each aid activity.14 The Institute for 
Health Metrics and Evaluation (IHME) produces esti-
mates of development assistance for health, which it 
disaggregates by health area, including reproductive 
and maternal health and neonatal and child health.15 
IHME’s approach includes key term searches to cate-
gorise activities directed towards RMNCH, excluding 
aid directed towards infectious diseases, the health 
system or the humanitarian or water and sanita-
tion sectors; it is applied to a combination of OECD 
disbursement data, other data sources and projec-
tions for more recent years.
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None of these aid tracking methods can currently 
be used to analyse domestic financing for RMNCH, 
which is a crucial component of the overall RMNCH 
resource envelope. Assessment of whether reductions 
in aid are offset by increases in domestic financing 
would be valuable; however, estimates of domestic 
financing for RMNCH are only available for selected 
years for selected low- income and middle- income 
countries16 17 and are very resource and time intensive 
to produce.18 19 With the Countdown to 2030, we are 
working to develop a Muskoka2- style algorithm that 
can be used to track domestic allocations to RMNCH 
in a timely and transparent manner.
CONCLUSION
While the Muskoka2 estimates published in 2020 painted 
a hopeful picture of a 10% increase in aid for RMNCH 
from 2016 to 2017,9 our updated findings, with two more 
years of data, are worrying. Our findings suggest that vola-
tile and falling RMNCH investments may have rendered 
RMNCH systems more fragile in the 2 years preceding 
Figure 1 Trends in aid for RMNCH, 2015–2019. Values cited in the text are restricted to donors reporting in both 2015 and 
2019 to avoid reporting bias in trends over time, as some donors did not report in all years. Panels show trends in aid for 
RMNCH: (A) disaggregated by donor, including both direct bilateral disbursements and core contributions to multilateral 
institutions from the top 10 largest donors over the time period and other bilateral and private donors; (B) disaggregated by 
type of donor deciding the purpose and recipient of the disbursement; (C) disaggregated by aid for child health, for maternal 
and newborn health and for the reproductive health of non- pregnant women; and (D) disaggregated by the World Bank country 
income group classification for recipient countries and regional and unspecified recipients. EU, European Union; RMNCH, 
reproductive, maternal, newborn and child health; USD, United States dollars.
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the COVID-19 pandemic. If World Bank predictions of 
falling overall global aid levels in 2021–202520 are correct, 
health and RMNCH in particular would need to be 
increasingly prioritised just to maintain recent RMNCH 
aid levels. A slight increase in the US global health aid is 
expected in 2021–2022,21 but the U—the second largest 
bilateral donor—has announced substantial cuts to the 
health and humanitarian sectors.22 In both countries, 
new commitments to COVID-19 and ‘global health secu-
rity’21 22 within stagnant or shrinking health aid budgets 
risk crowding out RMNCH at a time when more, not less 
investment is needed.
We present only the geographic and demographic 
destinations of aid; however, many other analyses are 
possible with these data. We therefore encourage 
everyone academics, advocates and policy makers—
to explore and exploit the Muskoka2 aid for RMNCH 
dataset,12 as well as the wider OECD aid datasets.11 Future 
work should further explore measures of aid effective-
ness, including the channels through which RMNCH 
funds are disbursed,7 23 and equity in the allocation and 
distribution of RMNCH aid.16 Such analyses are crucial 
to guide advocacy efforts to improve RMNCH outcomes, 
especially in low- income countries.
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